CCO Oncology Podcast

Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC

Episode Summary

Listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss 2 real-world cases of patients with HER2-positive MBC and clinical considerations in the evolving state-of-the-art care treatment landscape.

Episode Notes

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:

• Local therapy in the context of MBC
• Choice of therapy after progression on available standards of care
• Choice of trastuzumab deruxtecan and tucatinib based on patient presentation
• Managing patients with CNS metastases
• Managing interstitial lung disease

Presenters:
Thomas Bachelot, MD, PhD

Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Medical Oncology 
Centre Léon Bérard
Lyon, France

Adam M. Brufsky, MD, PhD
Professor of Medicine 
Hematology/Oncology 
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Cristina Saura, MD, PhD
Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebron University Hospital
Barcelona, Spain

Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc. 

Link to full program, including associated downloadable slidesets:
https://bit.ly/32A1HMb